-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Börse FrankfurtEURSymbol 0TB-
THERAVANCE BIOPHARMA INCBörse Börse FrankfurtEURSymbol 0TB
-
THERAVANCE BIOPHARMA INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol 0TB
-
THERAVANCE BIOPHARMA INCBörse Börse BerlinEURSymbol 0TB
-
THERAVANCE BIOPHARMA INCBörse Quotrix System der Börse DüsseldorfEURSymbol 0TB
-
THERAVANCE BIOPHARMA INCBörse Börse DüsseldorfEURSymbol 0TB
-
THERAVANCE BIOPHARMA INCBörse Börse StuttgartEURSymbol 0TB
-
ISIN KYG8807B1068 WKN: A1137VUSDSymbol TBPH
-
USDTheravance BiopharmaBörse Nasdaq
-
Symbol 0TB
Währung
EUR
Börse
Börse Frankfurt Zeitzone: America/New_York
Mitarbeiter
111
6 ETFs die in Theravance Biopharma investieren
Dir gefallen die Informationen zu Theravance Biopharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Theravance Biopharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Theravance Biopharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Theravance Biopharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
34 News & Informationen zur Theravance Biopharma Aktie
Were Hedge Funds Right About Impinj, Inc. (PI)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on…
Theravance Biopharma To Report Second Quarter 2021 Financial Results On August 3, 2021
DUBLIN, Ireland, July 20, 2021 /PRNewswire/ — Theravance Biopharma, Inc. TBPH, a diversified biopharmaceutical company primarily focused on the discovery,
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ju…
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ju…
Stocks That Hit 52-Week Lows On Thursday
Thursday's morning session saw 13 companies set new 52-week lows.
Things to Consider: Edgewise Therapeutics (NASDAQ:EWTX) was the largest …
Pre-market Movers: FFHL, NKE, LPG, MRIN…
(RTTNews) – The following are some of the stocks making big moves in Friday's pre-market trading (as of 4.30 A.M.) In the Green Fuwei Films (Hol…
Pre-market Movers: FFHL, NKE, LPG, MRIN…
The following are some of the stocks making big moves in Friday's pre-market trading (as of 4.40 A.M.).
Theravance Biopharma, Inc. : Announces Pricing of Public Offering of Ordinary Shares
DUBLIN, June 24, 2021 /PRNewswire/ — Theravance Biopharma, Inc. , a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of… | June 25, 2021
Theravance Biopharma, Inc. Announces Pricing Of Public Offering Of Ordinary Shares
DUBLIN, June 24, 2021 /PRNewswire/ — Theravance Biopharma, Inc. TBPH (“Theravance Biopharma”), a diversified biopharmaceutical company primarily focused on
Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares
/PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”), a diversified biopharmaceutical company primarily focused on the discovery,…
Theravance Biopharma, inc. announces proposed public offering of ordinary shares
Theravance Biopharma (TBPH)was down 10% to $15.39 post market while it announced an offering of its ordinary shares.The company also intends to grant the underwriters a 30-day option…
Theravance Biopharma, Inc. Announces Proposed Public Offering Of Ordinary Shares
DUBLIN, June 24, 2021 /PRNewswire/ — Theravance Biopharma, Inc. TBPH (“Theravance Biopharma”), a diversified biopharmaceutical company primarily focused on
Amazon, CureVac Rise Premarket; Coinbase Global Falls By Investing.com
Amazon, CureVac Rise Premarket; Coinbase Global Falls
Theravance Plunges As Candidate For Covid-Related Lung Injury Fails By Investing.com
Theravance Plunges As Candidate For Covid-Related Lung Injury Fails
Theravance Phase 2 Nezulcitinib Study Did Not Meet Primary Goal In Acute Lung Injury Due To COVID-19
(RTTNews) – Theravance Biopharma, Inc. (TBPH), a biopharmaceutical company primarily focused on organ-selective medicines, announced Monday that i…
CMC Materials to Release Financial Results for First Quarter of Fiscal 2021 After Market Close on February 3, 2021
Aurora, IL, Jan. 14, 2021 (GLOBE NEWSWIRE) — CMC Materials (Nasdaq: CCMP), a leading global supplier of consumable materials to semiconductor manufacturers and pipeline companies, announced the timing of its earnings release and conference call information for the first quarter of fiscal year 2021, which ended December 31, 2020. The earnings release, slide presentation and corresponding prepared remarks will be available in the Investor Relations section of the company’s website, cmcmaterials.com, after market close on Wednesday, February 3, 2021. Conference call: Thursday, February 4, at 10:00 a.m. Eastern Time Dial-in information: United States: (833) 714-0937 International: (778) 560-2685 Conference code: 4539453During the live call, the management team will begin with a brief synopsis of the quarter followed by a comprehensive question and answer session. ABOUT CMC MATERIALS, INC.CMC Materials, Inc. (Nasdaq: CCMP) is a global supplier of consumable materials to semiconductor manufacturers and pipeline companies. The company is a leader in developing high-quality, critical materials that enable superior performance for its customers. CMC Materials’ mission is to create value by delivering high-performing and innovative solutions that solve its customers’ greatest challenges. The company’s solutions play a critical role for its customers’ operations, including helping to enable the manufacturing of smaller, faster and more complex semiconductor devices, and enhancing operations and improving manufacturing efficiencies. The company has approximately 2,100 employees globally. For more information, visit http://www.cmcmaterials.com or contact Colleen Mumford, Vice President, Communications and Marketing, at 630-499-2600. CONTACT: Contact: Colleen Mumford Vice President, Communications and Marketing CMC Materials, Inc. (630) 499-2600
Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles
Diabetic Peripheral Neuropathy Pipeline Report helps in identifying emerging players in the market and their portfolios. The global Diabetic Peripheral Neuropathy therapeutic landscape evaluates based on mechanism of action (MoA), route of administration (RoA), phases of development, and molecule type.Los Angeles, USA, Jan. 14, 2021 (GLOBE NEWSWIRE) — Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles Diabetic Peripheral Neuropathy Pipeline Report helps in identifying emerging players in the market and their portfolios. The global Diabetic Peripheral Neuropathy therapeutic landscape evaluates based on mechanism of action (MoA), route of administration (RoA), phases of development, and molecule type. “Diabetic Peripheral Neuropathy Pipeline Analysis” by DelveInsight features the details around the Diabetic Peripheral Neuropathy pipeline landscape, unmet needs, and Diabetic Peripheral Neuropathy therapeutic assessment of the key pipeline therapies. Some of the chief Diabetic Peripheral Neuropathy Pipeline Highlights * 20+ key companies are working to strengthen the Diabetic Peripheral Neuropathy pipeline including the Regenacy Pharmaceuticals LLC, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pure Green, and several others. * Diabetic Peripheral Neuropathy market presents promising and a vast new product pipeline with pivotal trials, NME Projects and phase-advancing therapeutic candidates. * 15+ Pipeline therapies in different states of clinical development. Pipeline drugs profiled in the report include Ricolinostat, FE-SYHA1402, etc. * Collaborations and Deals * Pipeline Drug Profiles provided include: * Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others. * Phases of development of Diabetic Peripheral Neuropathy Drugs * Mechanism of Action * Route of Administration * Diabetic Peripheral Neuropathy Companies involved including originator, licensing companies, developer, investors, and others * New molecular entity details * Drug designations and other special status provided by regulatory authorities * Diabetic Peripheral Neuropathy Market Drivers and Barriers * Diabetic Peripheral Neuropathy Therapeutics Market LandscapeRequest for Diabetic Peripheral Neuropathy Pipeline Assessment Sample ReportDiabetic Neuropathy is nerve damage caused by diabetes. When it affects the arms, hands, legs, and feet, it is known as Diabetic Peripheral Neuropathy. Diabetic Peripheral Neuropathy pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and discovery. Diabetic Peripheral Neuropathy Emerging Drugs * FE-SYHA1402 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.ZhongQi Pharmaceutical Technology is conducting a multiple doses study to assess the safety, tolerability, pharmacokinetics of SYHA1402 in healthy candidates. This study comprises two parts: The objective of the food effect study (Part 1) is to evaluate the effect of food on the pharmacokinetic profiles of SYHA1402 tablets under fed and fasted conditions following the oral administration of SYHA1402. The aim of the multiple doses study (Part 2) is to examine the safety, tolerability, and Pharmacokinetics of SYHA1402 in healthy subjects following oral administration of multiple rising doses. Secondary objectives are the exploration of pharmacokinetics (PK) following multiple oral doses. * VM202 by HelixmithVM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy. VM202 is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms – a configuration that closely mimics HGF productions in humans that is required for optimal therapeutic benefits. Because there is no change in the coding region of the HGF gene, HGF proteins generated from VM202 are identical to wild-type human HGF proteins. * NYX-2925 by AptinyxNYX-2925 is a novel, oral small molecule NMDA receptor modulator in development for chronic pain treatment. Dysregulation of glutamatergic circuits in the brain is required in the development of centralized chronic pain. NYX-2925 is in late-stage clinical development across two chronic pain indications -Painful Diabetic Peripheral Neuropathy and Fibromyalgia. * LX9211 by Lexicon PharmaceuticalsLX9211 is a potent, orally delivered, selective small-molecule inhibitor of AAK1, a target discovered and extensively characterized in an alliance with Bristol Myers Squibb. Preclinical data displayed central nervous system penetration and lessen in pain behaviour in models of neuropathic pain. Lexicon has exclusive research, development, and commercialization rights to LX9211 and additional compounds acting through AAK1.For further product profiles, request @ Diabetic Peripheral Neuropathy Pipeline Analysis Sample ReportScope of Diabetic Peripheral Neuropathy Drug Pipeline Report * Coverage: Global * Major Players: 20+ Key Companies * Diabetic Peripheral Neuropathy Prominent Players: Regenacy Pharmaceuticals LLC, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pure Green, Helixmith Co., Ltd., Bayer, Aptinyx, Eliem Therapeutics (UK) Ltd., Lexicon Pharmaceuticals, WinSanTor, Inc, Haisco Pharmaceutical Group Co., Ltd., Eli Lilly and Company, Daiichi Sankyo Co., Ltd., Avazzia, Inc, POLYSAN Scientific & Technological Pharmaceutical Company, Achelios Therapeutics Inc, Applied Therapeutics, Bionevia Pharmaceuticals, Regenacy Pharmaceuticals, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals, and many others. * Key Drugs Profiles: 15+ Products * Diabetic Peripheral Neuropathy Drugs Profiles: Ricolinostat, FE-SYHA1402, CBD, Engensis, BAY1817080, NYX-2925 50, ETX-018810, LX9211, WST-057 (4% pirenzepine), HSK16149, LY3016859, Mirogabalin, Electrical Stimulation, Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), AT 001, BNV-222, Amitriptyline/ketamine, and many others. * Phases: * Diabetic Peripheral Neuropathy Therapies Late-stage (Phase III) * Diabetic Peripheral Neuropathy Therapies (Phase II) * Diabetic Peripheral Neuropathy Therapies (Phase I) * Diabetic Peripheral Neuropathy Therapies Pre-clinical stage and Discovery candidates * Discontinued and Inactive candidates * Molecule Types: * Small molecule * Gene Therapies * Route of Administration: * Infusion * Intradermal * Intramuscular * Intranasal * Intravaginal * Oral * Parenteral * Subcutaneous * Topical * Product Types: * Mono * Combination * Mono/Combination Key Questions regarding Current Diabetic Peripheral Neuropathy Drug Treatment Landscape and Emerging Therapies Answered in the Pipeline Report * What are the current options for Diabetic Peripheral Neuropathy treatment? * How many companies are developing therapies for the treatment of Diabetic Peripheral Neuropathy? * How many Diabetic Peripheral Neuropathy emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Diabetic Peripheral Neuropathy? * What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Diabetic Peripheral Neuropathy market? * Which are the dormant and discontinued products and the reasons for the same? * What is the unmet need for current therapies for the treatment of Diabetic Peripheral Neuropathy? * What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Diabetic Peripheral Neuropathy therapies? * What are the key designations that have been granted for the emerging therapies for Diabetic Peripheral Neuropathy? * How many patents are granted and pending for the emerging therapies for the treatment of Diabetic Peripheral Neuropathy? Table of Contents 1Introduction 2Executive Summary of Diabetic Peripheral Neuropathy 3Diabetic Peripheral Neuropathy Overview 4Diabetic Peripheral Neuropathy Pipeline Therapeutics 5Diabetic Peripheral Neuropathy Therapeutic Assessment 6Diabetic Peripheral Neuropathy – DelveInsight’s Analytical Perspective 7Diabetic Peripheral Neuropathy Late Stage Products (Phase III) 7.1Engensis: Helixmith Co., Ltd. 8Diabetic Peripheral Neuropathy Mid Stage Products (Phase II) 8.1Aptinyx: NYX-2925 8.2LX9211: Lexicon Pharmaceuticals 9Diabetic Peripheral Neuropathy Early Stage Products (Phase I) 9.1FE-SYHA1402: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 9.2SR419: SIMR (Australia) Biotech Pty Ltd. 10Diabetic Peripheral Neuropathy Pre-clinical and Discovery Stage Products 11Diabetic Peripheral Neuropathy Inactive Products 12Diabetic Peripheral Neuropathy Comparative Analysis 13Diabetic Peripheral Neuropathy Key Companies 14Diabetic Peripheral Neuropathy Key Products 15Company-University Collaborations (Licensing/Partnering) Analysis 16Diabetic Peripheral Neuropathy Unmet Needs 17Diabetic Peripheral Neuropathy Market Drivers and Barriers 18Diabetic Peripheral Neuropathy- Future Perspectives and Conclusion 19Diabetic Peripheral Neuropathy Analyst Views 20Appendix Browse Detailed TOC, Emerging Drugs and Key Companies @ Diabetic Peripheral Neuropathy Pipeline Analysis ReportRelated Reports * Diabetic Peripheral Neuropathy Market Analysis DelveInsight's Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology. * Diabetic Peripheral Neuropathy Epidemiology Forecast Analysis DelveInsight’s ‘Diabetic Peripheral Neuropathy Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in 7MM. * Dementia with Diabetes Market Analysis DelveInsight's Dementia with Diabetes Market Insights, Epidemiology, and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology. * Diabetic Foot Market Analysis DelveInsight's Diabetic Foot Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. * Diabetic Gastroparesis Market Analysis DelveInsight's Diabetic Gastroparesis Market Research Report presents a detailed analysis of the market listing Diabetic Gastroparesis Epidemiology, Drug therapies, market trends in 7MM. * Diabetic Kidney Disease Market Analysis DelveInsight's Diabetic Kidney Disease (DKD) Market Insights, Epidemiology, and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. * Diabetes Market Analysis DelveInsight's Diabetes Market Insights, Epidemiology, and Market Forecast – 2030 report provides thorough insights on epidemiology and market trends.About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. CONTACT: Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187 http://www.delveinsight.com
Doug Goss Installed as President of Santa Clara County Association of REALTORS®
San Jose, CA, Jan. 14, 2021 (GLOBE NEWSWIRE) — The Santa Clara County Association of REALTORS® (SCCAOR) installed Doug as its President during a virtual ceremony on January 7, 2021. He will serve as the 2021 President of SCCAOR, a real estate trade organization that represents over 6,400 REALTOR® and Affiliate members in Santa Clara County.“I am honored to represent the Santa Clara County Association of REALTORS® this year for their 125th Anniversary,
Melcor REIT announces a 17% increase to Q1-2021 distributions
EDMONTON, Alberta, Jan. 14, 2021 (GLOBE NEWSWIRE) — Melcor Real Estate Investment Trust (TSX: MR.UN) announces that the REIT’s Board of Trustees met to confirm Q1-2021 distributions and several other matters. Ralph Young, Chair of the Board commented: “I am pleased to report to unitholders, on behalf of the Board, that business conditions, financial results and our outlook for 2021 have precipitated a 17% increase to our distributions for the first quarter of 2021. In addition, we have reviewed and considered other measures that were undertaken in order to preserve cash at the beginning of the COVID pandemic. * The Board approved Q1 distributions of $0.035 per unit for each of the first three months of 2021. This represents a 17% increase over distributions for the previous three quarters. Distribution decisions will be made quarterly based on conditions at that time. The distributions will be payable as follows:MonthRecord DateDistribution DateDistribution Amount January 2021January 29, 2021February 16, 20210.035 per unit February 2021February 26, 2021March 15, 20210.035 per unit March 2021March 31, 2021April 15, 20210.035 per unit * The Board reviewed the reinstatement of the Normal Course Issuer Bid; however, have determined that the decision will have to await the completion of the regularly scheduled year-end trading blackout. The Board will review their decision when the Automatic Share Purchase Plan can be reactivated. * The Board has also formally established an Independent Committee to examine and recommend regular renewals and/or amendments to agreements between Melcor Developments Ltd. and the REIT and other matters as directed by the Board. The Independent Committee will be chaired by independent and Lead Trustee Larry Pollock. The Board of Trustees remains committed to preserving and enhancing value for all Unitholders.Q4/Fiscal Year 2020 Conference Call Earnings Announcement & Conference Call.Melcor REIT also announces that results for Q4/FY-2020 will be released on March 4, 2021 after market close. Management will host a conference call at 11:00 am ET (9:00 am MT) on Friday, March 5, 2021.Toronto & Area: 1-416-915-3239 Toll Free: 1-800-319-4610Webcast & ReplayThe call will also be webcast (listen only) at https://www.gowebcasting.com/11057. A replay of the call will be available at the same URL shortly after the call is concluded.About Melcor REITMelcor REIT is an unincorporated, open-ended real estate investment trust. Melcor REIT owns, acquires, manages and leases quality retail, office and industrial income-generating properties in Western Canada. Its portfolio is currently made up of interests in 39 properties representing approximately 3.21 million square feet of gross leasable area located across Alberta and in Regina, Saskatchewan and Kelowna, British Columbia. For more information, please visit http://www.melcorREIT.ca.Forward-Looking StatementsThis press release may contain forward‐looking information within the meaning of applicable securities legislation, which reflects the REIT's current expectations regarding future events. Forward‐looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the REIT's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking information. Such risks and uncertainties include, but are not limited to, general and local economic and business conditions; the financial condition of tenants; the REIT’s ability to refinance maturing debt; leasing risks, including those associated with the ability to lease vacant space; and interest rate fluctuations. The REIT’s objectives and forward‐looking statements are based on certain assumptions, including that the general economy remains stable, interest rates remain stable, conditions within the real estate market remain consistent, competition for acquisitions remains consistent with the current climate and that the capital markets continue to provide ready access to equity and/or debt. All forward‐looking information in this press release speaks as of the date of this press release. The REIT does not undertake to update any such forward‐looking information whether as a result of new information, future events or otherwise.Additional information about these assumptions and risks and uncertainties is contained in the REIT’s filings with securities regulators. CONTACT: Contact Information: Investor Relations Nicole Forsythe Tel: 780.945.4707 Tel:1.855.673.6931 (x4707) ir@melcorREIT.ca
4 Peter Lynch Growth Stocks With Good Financial Strength
Stocks have high cash-to-debt ratios
Nasdaq Halts Generations Bancorp NY, Inc.
NEW YORK, Jan. 14, 2021 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted today in Generations Bancorp NY, Inc. (Nasdaq: GBNY) at 17:10:16 Eastern Time on January 14, 2021, for “additional information requested” from the company at a last sale price of $10.01. Trading will remain halted until Generations Bancorp NY, Inc. has fully satisfied Nasdaq’s request for additional information.For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.NDAQONasdaq Media Contact: Bianca Fata Bianca.Fata@nasdaq.com
AgilePoint Announces New Connectivity
Today AgilePoint, Inc. announced the launch of their new Microsoft Power Automate connector.
ITAÚ UNIBANCO HOLDING S.A.: Material Fact: Payment of Complementary Dividends
ITAÚ UNIBANCO HOLDING S.A. informs its stockholders that its Board of Directors approved as of today, January 14, 2021, the payment up to April 30, 2021 of the following earnings to stockholders, based on the final stockholding position recorded on January 22, 2021:
Walker & Dunlop Announces Fourth Quarter and Full-Year 2020 Earnings Webcast Details
Walker & Dunlop, Inc. (the “Company”) announced today that it will release its fourth quarter and full-year 2020 results before the market opens on February 4, 2021.
Action Against Hunger Warns of Potential Food Emergency as Violence Rocks the Central African Republic
Humanitarian access to people in need is impossible in many placesNew York, NY, Jan. 14, 2021 (GLOBE NEWSWIRE) — (via NGO Wire) A wave of violence has broken out across the Central African Republic following disputed elections on December 27, 2020. Major supply routes have been closed, leading to food shortages and rising food prices. Experts estimate that 30,000 people have fled to neighboring countries and more than 60,000 have been internally displaced.Prior to the current unrest, experts had predicted that one in nine people may be pushed to the brink of famine (IPC stage 4) by May 2021. More than half the population – 2.3 million people – were expected to suffer acute food security, and now violence is worsening the situation. The conflict threatens to create a humanitarian disaster, particularly if conflict continues to restrict humanitarian access and leave vulnerable populations without essential aid. Speaking from Bangui, Action Against Hunger’s Country Director in C.A.R., Mathilde Lambert said:
SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, NY / ACCESSWIRE / January 14, 2020 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Cardtronics Plc (CATM) relating to its proposed acquisition by affiliates of Apollo Global Management, Inc. and Hudson Executive Capital LP.
Lennar Replenishes Stock Repurchase Authorization, Up to $1.0 Billion
Lennar Corporation (NYSE: LEN and LEN.B), one of the nation's leading homebuilders, announced that its Board of Directors authorized the Company to repurchase from time to time up to the lesser of $1 billion in value, or 25,000,000 in shares, of the Company's outstanding Class A or Class B common stock. The repurchase authorization has no expiration date. The purpose of the authorization is to enable the Company to purchase shares from time to time when its officers deem it appropriate for the Company to do so. Under a prior stock repurchase authorization, which was approved by the Board in January 2019 and was replaced by the current one, the Company repurchased 14 million shares of its Class A and Class B common stock for a total of $781 million.
Lennar Corporation Declares Quarterly Dividends
Lennar Corporation (NYSE: LEN and LEN.B), one of the nation's leading homebuilders, announced that its Board of Directors has declared a quarterly cash dividend of $0.25 per share for both Class A and Class B common stock payable on February 12, 2021 to holders of record at the close of business on January 29, 2021.
Liberty All-Star Equity Fund December 2020 Monthly Update
Below is the December 2020 Monthly Update for the Liberty All-Star Equity Fund. (NYSE: USA)
Cambia Health Foundation Announces 12 New Sojourns® Scholars and the Leadership Program's 2021 Call for Applications
Cambia Health Foundation announces the seventh cohort of scholars accepted into its Sojourns® Scholar Leadership Program. Twelve emerging palliative care leaders were carefully chosen through a rigorous selection process from a highly competitive pool. In addition, the Foundation has opened the 2021 Sojourns® Scholar Leadership Program Call for Applications and encourages palliative care professionals from across the country, including all disciplines and practice settings to apply.
LAWSUITS FILED AGAINST PINS, TRIT and TCDA – Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / January 14, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, FIII, JWS and BRPA Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
$13.1 Billion Worldwide Organic Personal Care Products Industry to 2027 – Impact of COVID-19 on the Market
The
Theravance Biopharma : To Present at the 39th Annual J.P. Morgan Healthcare Conference
DUBLIN, Jan. 5, 2021 /PRNewswire/ — Theravance Biopharma, Inc. , a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective… | January 5, 2021